PA-082

Overview

PA-082 is a selective PPAR-γ modulator that functions as a partial agonist. PA-082 causes partial recruitment of SRC1, TIF2, SRC3 and full recruitment of PGC1-α to PPAR-γ ligand-binding domain. PA-082 prevents triglyceride accumulation during de novo adipogenesis and antagonizes Rosiglitazone ( HY-17386 )-induced lipid accumulation. PA-082 potentiates insulin-stimulated glucose uptake in adipocytes and protects against TNFα-induced insulin resistance. PA-082 can be used for the research of type 2 diabetes.

Application

Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > Type 2 Diabetes | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Vitamin D Related/Nuclear Receptor | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > PPAR | Products > Signaling Pathways > PGC-1α

Product Information

• Catalog No.: HY-180398
• CAS No.: 95520-87-9
• Molecular Formula: C33H38N2O5
• Molecular Weight: 542.68
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source